Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 in c-Met-positive advanced digestive system malignancies
NCT05628857Phase 2Completed
- Sponsor
- RemeGen
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of RC108 in gastric cancer (GC), colorectal cancer (CRC), liver cancer and 3 more (4 cohorts), sponsored by RemeGen. Primary endpoint: Objective Response Rate at 24 months. Started Nov 2022; status: completed.
02
Drugs
RC108
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)liver canceresophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05628857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628857.